GNI Group Ltd. — Investor Relations & Filings
Filings indexed
93
across all filing types
Latest filing
2026-05-08
Regulatory Filings
Country
JP
Japan
Listing
T
2160
GNI Group Ltd. is a vertically integrated, multinational biopharmaceutical company engaged in the full spectrum of drug development, from research and clinical trials to manufacturing, sales, and marketing. The company's portfolio includes pharmaceutical drugs, traditional Chinese medicines, and medical devices. Its research and development efforts are primarily focused on creating therapies for diseases such as cancer and inflammation, with a particular emphasis on conditions prevalent in Asian populations. The group utilizes genetic information and analysis technology to advance its drug discovery programs.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 当社子会社Gyre Therapeuticsによる2026年度第１四半期の決算概要および事業ハイライトについて | 2026-05-08 | Japanese | |
| 代表執行役の異動（追加選定）および子会社役員の人事異動に関するお知らせ | 2026-05-07 | Japanese | |
| （開示事項の経過）Gyre Therapeutics, Inc.によるCullgen Inc.の完全子会社化完了に関するお知らせ | 2026-05-07 | Japanese | |
| がん関連肺合併症への適応拡大に向けたピルフェニドンの第１例目の被験者登録完了のお知らせ | 2026-04-20 | Japanese | |
| Gyre Therapeutics による Proxy Statement（株主総会招集通知）提出 およびGyre Therapeutics株式の発行関連議案に関するお知らせ | 2026-04-17 | Japanese | |
| 確認書 | 2026-03-27 | Japanese |
Browse filings by year
12 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 46881760 | 当社子会社Gyre Therapeuticsによる2026年度第１四半期の決算概要および事業ハイライトについて | 2026-05-08 | Japanese | ||
| 46881698 | 代表執行役の異動（追加選定）および子会社役員の人事異動に関するお知らせ | 2026-05-07 | Japanese | ||
| 46881696 | （開示事項の経過）Gyre Therapeutics, Inc.によるCullgen Inc.の完全子会社化完了に関するお知らせ | 2026-05-07 | Japanese | ||
| 46877795 | がん関連肺合併症への適応拡大に向けたピルフェニドンの第１例目の被験者登録完了のお知らせ | 2026-04-20 | Japanese | ||
| 46877777 | Gyre Therapeutics による Proxy Statement（株主総会招集通知）提出 およびGyre Therapeutics株式の発行関連議案に関するお知らせ | 2026-04-17 | Japanese | ||
| 33055814 | 確認書 | 2026-03-27 | Japanese | ||
| 33055813 | 有価証券報告書－第25期(2025/01/01－2025/12/31) | 2026-03-27 | Japanese | ||
|
2025
8 filings
| |||||
| 10964439 | 訂正報告書（大量保有報告書・変更報告書） | 2025-12-25 | Japanese | ||
| 10860846 | 変更報告書 | 2025-12-24 | Japanese | ||
| 7857814 | 確認書 | 2025-08-14 | Japanese | ||
| 7857791 | 半期報告書－第25期(2025/01/01－2025/12/31) | 2025-08-14 | Japanese | ||
| 7859825 | 訂正臨時報告書 | 2025-07-25 | Japanese | ||
| 7859879 | 訂正臨時報告書 | 2025-07-24 | Japanese | ||
| 7266395 | 臨時報告書 | 2025-04-23 | Japanese | ||
| 7269644 | 確認書 | 2025-03-31 | Japanese | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Ajanta Pharma Ltd.
Specialty pharmaceutical firm focused on complex generics a…
|
AJANTPHARM | IN | Manufacturing |
|
Akari Therapeutics Plc
Develops next-gen antibody-drug conjugates using proprietar…
|
AKTX | US | Manufacturing |
|
Akebia Therapeutics, Inc.
A biopharmaceutical company that develops and commercialize…
|
AKBA | US | Manufacturing |
|
Akeso, Inc.
Global commercial-stage biopharma developing innovative ant…
|
9926 | KY | Manufacturing |
|
Aktis Oncology, Inc.
A clinical-stage biotech developing targeted alpha radiopha…
|
AKTS | US | Manufacturing |
|
Akums Drugs and Pharmaceuticals Limited
CDMO providing end-to-end pharmaceutical manufacturing and …
|
AKUMS | IN | Manufacturing |
|
Albert David Ltd.
Produces pharmaceutical formulations, infusions, and specia…
|
ALBERTDAVD | IN | Manufacturing |
|
Aldeyra Therapeutics, Inc.
Develops medications for immune-mediated ocular and systemi…
|
ALDX | US | Manufacturing |
|
Aleafia Health Inc.
Vertically integrated cannabis company with cultivation, pr…
|
AH | CA | Manufacturing |
|
Alector, Inc.
Clinical-stage biotech using immuno-neurology to treat neur…
|
ALEC | US | Manufacturing |
GNI Group Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/13513/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=13513 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=13513 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=13513 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 13513}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for GNI Group Ltd. (id: 13513)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.